Clinical trial NCT05277766 - References

Colorectal Cancer — Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

Citation(s)

•   Ahn BJ, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS
  Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration. Eur J Clin Pharmacol. 2010 Dec;66(12):1235-45. doi: 10.1007/s00228-010-0885-3. Epub 2010 Sep 9.
•   Alyami M, Hubner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V
  Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019 Jul;20(7):e368-e377. doi: 10.1016/S1470-2045(19)30318-3.
•   Chabot GG
  Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. doi: 10.2165/00003088-199733040-00001.
•   Cheung YK, Chappell R
  Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000 Dec;56(4):1177-82. doi: 10.1111/j.0006-341x.2000.01177.x.
•   Dai J, Chen Y, Gong Y, Wei J, Cui X, Yu H, Zhao W, Gu D, Chen J
  The efficacy and safety of irinotecan +/- bevacizumab compared with oxaliplatin +/- bevacizumab for metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore). 2019 Sep;98(39):e17384. doi: 10.1097/MD.0000000000017384.
•   Dakwar GR, Shariati M, Willaert W, Ceelen W, De Smedt SC, Remaut K
  Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - Mission possible? Adv Drug Deliv Rev. 2017 Jan 1;108:13-24. doi: 10.1016/j.addr.2016.07.001. Epub 2016 Jul 13.
•   Demtroder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA
  Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis. 2016 Apr;18(4):364-71. doi: 10.1111/codi.13130.
•   Di Giorgio A, Sgarbura O, Rotolo S, Schena CA, Bagala C, Inzani F, Russo A, Chiantera V, Pacelli F
  Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma. Ther Adv Med Oncol. 2020 Jul 24;12:1758835920940887. doi: 10.1177/1758835920940887. eCollection 2020.
•   Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB
  Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006 Mar 15;66(6):3271-7. doi: 10.1158/0008-5472.CAN-05-4007.
•   Gockel I, Jansen-Winkeln B, Haase L, Niebisch S, Moulla Y, Lyros O, Lordick F, Schierle K, Wittekind C, Thieme R
  Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. Tumori. 2020 Feb;106(1):70-78. doi: 10.1177/0300891619868013. Epub 2019 Aug 30.
•   Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, Germer CT, Pelz JO
  Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013 Apr 16;108(7):1432-9. doi: 10.1038/bjc.2013.82. Epub 2013 Mar 19.
•   Kurtz F, Struller F, Horvath P, Solass W, Bosmuller H, Konigsrainer A, Reymond MA
  Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study. Gastroenterol Res Pract. 2018 Oct 24;2018:2743985. doi: 10.1155/2018/2743985. eCollection 2018.
•   Lamb YN, Scott LJ
  Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. Drugs. 2017 May;77(7):785-792. doi: 10.1007/s40265-017-0741-1.
•   Nielsen M, Graversen M, Ellebaek SB, Kristensen TK, Fristrup C, Pfeiffer P, Mortensen MB, Detlefsen S
  Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. J Clin Pathol. 2021 Jan;74(1):19-24. doi: 10.1136/jclinpath-2020-206607. Epub 2020 May 8.
•   Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF
  Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015 Aug;4(8):1171-7. doi: 10.1002/cam4.459. Epub 2015 Apr 18.
•   Ploug M, Graversen M, Pfeiffer P, Mortensen MB
  Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. BMC Cancer. 2020 Feb 10;20(1):105. doi: 10.1186/s12885-020-6572-6.
•   Shariati M, Willaert W, Ceelen W, De Smedt SC, Remaut K
  Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis. Cancers (Basel). 2019 Jun 28;11(7):906. doi: 10.3390/cancers11070906.
•   Taibi A, Geyl S, Salle H, Salle L, Mathonnet M, Usseglio J, Durand Fontanier S
  Systematic review of patient reported outcomes (PROs) and quality of life measures after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Oncol. 2020 Dec;35:97-105. doi: 10.1016/j.suronc.2020.08.012. Epub 2020 Aug 20.
•   Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group
  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum In: Lancet. 2016 Feb 6;387(10018):536.
•   Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK
  Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1141-5. doi: 10.1007/s00280-008-0839-y. Epub 2008 Oct 7.

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study

Details for clinical trial NCT05277766